Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Naltrexone And Bupropion

Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders

Orexigen Therapeutics, Inc · Phase 2/3 · Completed · Enrollment 3

NCT03946111

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Naltrexone/Bupropionn/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Naltrexone/Bupropion: endpoint not reported
  • Placebo: endpoint not reported